Q3 2025 Natco Pharma Ltd Earnings Call Transcript

Feb 13, 2025 / 04:30AM GMT

Release Date Price: ₹975.05 (-20.00%)

Transcript

Key Points

Positve

Natco Pharma Ltd (BOM:524816) expects healthy growth in the upcoming quarters due to new product allocations and launches.
The company has a significant cash reserve of INR3,264 crore, providing a strong financial position for potential acquisitions.
Natco Pharma Ltd (BOM:524816) anticipates a substantial market share allocation for Revlimid in the next year, which could boost revenues.
The company is actively pursuing strategic acquisitions to strengthen its US and ROW (Rest of the World) business segments.
Natco Pharma Ltd (BOM:524816) has received two new product approvals, which are expected to positively impact future earnings.

Negative

Natco Pharma Ltd (BOM:524816) reported a decline in consolidated total revenue and net profit compared to the same period last year.
The absence of Revlimid sales significantly impacted the company's performance in the current quarter.
High R&D expenses have contributed to the weaker financial performance, with ongoing projects causing a cash flow mismatch.
The company's export formulation business saw a decline, affecting overall revenue.
There is uncertainty regarding the timing and impact of future product launches, including potential delays in regulatory approvals.

Operator

Ladies and gentlemen, good day and welcome to the Natco Pharma Q3 and nine months FY25 earnings conference call hosted by Batliwala and Karani Securities India Private Limited.

(Operator Instructions) Please note that this conference is being recorded.

I now hand the conference over to Mr. Rishikesh Patole from Batliwala and Karani Securities India Private Limited. Thank you and over to you, sir.

Rishikesh Patole;Rajesh Chebiyam

Batlivala & Karani Securities India Pvt Ltd - Analyst;Natco Pharma Ltd - Executive

Thank you. Good morning, everyone. On behalf of the B&K Securities, I welcome you all to the Q3 FY25 earnings conference call of Natco Pharma. Hope everyone is in good health and doing well.

On behalf of Natco today we have with us Mr. Rajeev Nannapaneni, Director and CEO; Mr. Rajesh Chebiyam, Executive Vice President, Crop Health Sciences.

I now hand over the call to Rajesh for the management's opening remarks post which we will open the session for Q&A. Over to you, sir.

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.